Riding a Trending Study Without Making a Disease Claim
A new sleep study is trending. It's a solid piece of research on magnesium glycinate and sleep onset, it's all over the wellness press, and your supplement brand sells a magnesium product. Every hour you don't publish, a competitor is picking up the traffic.
Your content lead drafts something in forty minutes. It's good. It's also a lawsuit-shaped object, because the third paragraph says your product “helps treat insomnia.”
If you market supplements in the US, you know exactly why that sentence can't ship. Under DSHEA, a supplement can carry structure/function claims — “supports restful sleep” — but the moment your copy says a product treats, cures, or preventsa disease, you've made an implied drug claim. Insomnia is a diagnosable condition. That one verb reclassifies your marketing in the eyes of the FDA, and the FTC's substantiation rules sit right behind it: civil penalties for deceptive health claims can run up to $50,120 per violation — and “per violation” is not your friend when the claim ran across a blog post, three social channels, and a video.
So the draft goes to review. Review takes days, because the reviewer is careful and busy. The trend is over in a week. This is the regulated-content trap: the speed the market rewards is exactly the speed your risk posture can't allow — as long as compliance is a human reading finished drafts at the end of the line.
Move the gate to the front
Verity's answer is to make compliance a stage of production, not an afterthought of it. Here's the same trending-study morning, run through the engine.
Research, claim by claim.You give Verity the topic. It researches the study and the surrounding evidence, and builds the draft as a set of discrete claims, each mapped to a specific source. “The study followed participants over eight weeks” points at the study. “Magnesium contributes to normal nervous system function” points at its own support. Nothing floats unsourced.
The gate catches the sentence your reviewer would have caught — instantly. The draft passes through a compliance gate before any human reads it: rule-based checks encoding the DSHEA lens, plus an LLM judge for the phrasings a regex can't see. That “helps treat insomnia” line is flagged on sight — treatsplus a disease condition — and the gate proposes what a careful editor would: reframe to a structure/function claim, “supports healthy sleep onset,” hedged to what the cited evidence actually supports. The same checks scan the title, catch the sneaky variants (“self-treat,” “may cure”), and auto-inject the FDA disclaimer supplements are required to carry. Flagged claims cannot be waved through in bulk; each one waits for an explicit human decision.
One human approval — of claims, not vibes.Your reviewer opens the claim map: every statement in the draft, side by side with its evidence and the gate's verdict. Approve, edit, or reject, claim by claim, then sign off once. That review takes minutes instead of days, because the reviewer is judging evidence that's already assembled — not hunting for landmines in prose. And the sign-off is recorded: who approved, what they saw, which policy version ran.
Fan-out, same evidence underneath. One approval releases the campaign: the blog post, a video, LinkedIn, Instagram, X, Facebook, Bluesky — each formatted for its channel, all built from the same approved claim set. You caught the trend the same day, and every asset that shipped is one you can defend.
The certificate your customers can scan
Here's the part that turns compliance from pure cost into something your audience can see. Every published asset carries a public Trust Certificate — a page anyone can open, linked from a badge and QR code on the article itself.
A skeptical reader — and wellness readers have earned their skepticism — scans the code and sees the trust record behind the post: who published it, which sources were used, how many claims were checked, that a human reviewer signed off, and the disclaimers that apply. To be precise about what that is: the certificate attests that the content has a verifiable trust record — sources, checks, reviewer, disclaimers. It doesn't declare the content infallible. That precision is the point. In a feed full of anonymous AI health copy, “here is exactly how this was made, and who stood behind it” is a differentiator you can print on the page.
Your compliance officer gets the other half: a full audit trail per campaign — trigger, sources, claim decisions, approvals — ready the day anyone asks, instead of reconstructed from email threads the week after.
Know the price before you commit
Video is where regulated brands hesitate twice: once on compliance, once on budget — agency quotes arrive late, vague, and rarely twice the same.
Verity prices video up front. Two controls and a live price: a length slider, and a presenter densitychoice — how much on-camera presenter versus slides and b-roll. Want a three-minute explainer that's mostly your presenter on camera? The price updates as you move the sliders, before you commit anything. More presenter time costs more and renders slower; the trade-off is yours to make, with the number in front of you. You pick, you see the price, you commit — and the engine renders exactly what you bought. No quote cycle, no surprise invoice, no “it depends.”
The same trap, other industries
Wellness is the sharpest version of this story, but swap the nouns and it's finance (“guaranteed returns” instead of “cures”) or healthcare adjacency (anything that drifts toward diagnosis). The pattern is identical everywhere content meets a regulator: the market moves in hours, unreviewed publishing is unacceptable, and the fix is not braver copywriters — it's a pipeline where every claim is sourced, gated, and human-approved before it ships, with the record to prove it afterward.
The brands that win regulated categories won't be the ones that publish recklessly or the ones that publish nothing. They'll be the ones that publish fast with receipts.
Next trending study, be first — with an audit trail. Request access to the private beta.